Background
==========

Non-small cell lung cancer (NSCLC) remains one of the most common cancers in China and in the world \[[@B1]\]. Although surgery is the main curative treatment, postoperative recurrence ranges from 30% to 50% \[[@B2]\]. Positive results of recent clinical trials, including the International Adjuvant Lung Cancer Trial (IALT), the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG JBR.10) and the Adjuvant Navelbine International Trialist Association (ANITA), provide preliminary confirmation on the role of adjuvant chemotherapy, showing that platinum-based postoperative chemotherapy offers a significant 5-year survival benefit compared with surgery alone \[[@B3]-[@B5]\]. However, only 5%-15% of the individuals who received adjuvant chemotherapy achieved long-term survival improvement \[[@B6]\]. Therefore, it is very important to select subgroups of patients who are most likely to benefit from postoperative chemotherapy and who are potentially resistant to a given chemotherapy regimen. Recent studies have shown that expression of excision repair cross-complementation group 1 (ERCC1), ribonucleotide reductase subunit M1 (RRM1) and class III beta-tubulin (β-tubulinIII) could provide predictive value for patients treated with platinum agents, gemcitabine (GEMZ) and microtubule-interacting agents (including taxanes and vinorelbine (NVB)), respectively \[[@B7]\].

Topoisomerase II alpha (TopIIα) is a nuclear enzyme that catalyzes the conversion between DNA topological isomers and can be detected in cells with high proliferative activity. Many anticancer agents (i.e., anthracyclines) exert anticancer effects by stabilizing DNA cleavage and inhibiting DNA replication via binding and blocking the activity of TopIIα \[[@B8]\]. TopII-inhibiting chemotherapeutic agents, including irinotecan, etoposide and topotecan, are commonly used for the treatment of small cell lung cancer (SCLC), but they are seldom used for the treatment of NSCLC. However, it has been reported that one type of multidrug resistance (MDR) in lung cancer, atypical MDR, is mediated through an altered expression of TopII. This type of resistance was found to be associated either with decreased TopIIα expression or with a mutation that altered the interaction of the enzyme with the drug or DNA \[[@B9]\]. High TopIIα expression has been observed in many kinds of cancers, including breast cancer and NSCLC \[[@B10]-[@B13]\]. Although TopIIα expression and its implication for TopII inhibitors have been extensively investigated in several cancers, especially in breast cancer, few reports have described TopIIα expression and its cross resistance to other cytotoxic drugs in NSCLC \[[@B10],[@B11],[@B14]-[@B16]\]. In addition, some studies have reported that low levels of TopIIα gene or protein expression might be related with resistance not only to TopII inhibitors, such as etoposide and anthracycline, but also to other cytotoxic drugs, such as cisplatin, microtubule-interacting agents and gemcitabine, in some cancer cell lines or cancers \[[@B17]-[@B19]\]. However, little is known about the correlation between TopIIα expression, which can mediate cross resistance, and the effect of common chemotherapy drugs, including cisplatin, microtubule-interacting agents and GEMZ, in postoperative NSCLC.

To assess whether TopIIα might be a valuable biomarker in postoperative NSCLC patients who received chemotherapy, TopIIα expression levels in tumor samples were evaluated, and the prognostic and therapeutic predictive roles of TopIIα were analyzed. Ki67, another molecular marker that is related to proliferation, was evaluated as a control factor.

Methods
=======

Patient data
------------

Patients who underwent curative surgery for NSCLC between January 2004 and December 2007 received at least two cycles of adjuvant chemotherapy within two months after surgery in the General Hospital of Chinese People\'s Liberation Army (CPLA), and for whom a formalin-fixed, paraffin-embedded sample adequate for analysis was available, were included in the study. Patients who received neoadjuvant chemotherapy or neoadjuvant radiotherapy were excluded.

Data concerning clinicopathological features, including age, sex, smoking history, histological subtypes, pathological TNM stage, surgical methods, chemotherapy regimens and cycles, other treatments such as adjuvant radiotherapy, date of recurrence or metastasis, and survival information, were obtained by medical records, outpatient and telephone follow-ups. Outcome data including disease free survival (DFS) and overall survival (OS) were calculated. Clinical data were kept unavailable during immunohistochemistry (IHC). The study design and procedure involving the human tissue sample collection were reviewed and approved by the ethical board of the General Hospital of CPLA.

Immunohistochemistry
--------------------

Representative tumor paraffin-embedded blocks were selected and collected, after two pathologists reviewed, the tumor sample slices stained with hematoxylin and eosin (HE). Sections (4 μm thick) were cut from tumor specimens, placed onto 3-amino-propyltriethoxy-silane (APES) slides, and deparaffinized in xylene and gradient ethanol. Antigen retrieval was performed by placing slides in a high-pressure cooker in a 0.01 mM citrate buffer, pH 6.0, for 2.5 min at 100°C; they were then cooled for 20 min. Endogenous peroxidase activity was blocked by incubating the section in 3% H~2~O~2~for 10 min, followed by rinsing in PBS solution three times. Immunohistochemical staining was performed with the two-step EnVision(tm)+ System Kit (Dako, Denmark). The sections were incubated with mouse anti-TopIIα monoclonal primary antibodies (clone 3F6, 1/75 dilution, Novocastra, UK) or mouse anti-Ki67 monoclonal primary antibodies (clone MIB1, 1/200 dilution, Dako) at 37°C for 60 min, followed by dextran polymer conjugated with horseradish peroxidase enzyme and secondary anti-mouse antibody (Dako). Slides were stained with 3,3\'-diaminobenzidine tetrahydrochloride (DAB) chromogen and counter-stained with hematoxylin. Negative controls were conducted by adding PBS solution instead of the primary antibody, and positive controls were conducted by staining known-positive samples from our pathology specimen bank.

All the specimens were examined and scored by two independent pathologists without the knowledge of patient data, and their inter-observer concordance was over 90%. The number of positive cells in 1,000 tumor cells within 10 microscopic fields at ×200 magnification was counted and scored as follows: 0 (negative, \<25%), 1 (focal, 25% to 49%), 2 (moderate, 50% to 74% ), 3 (diffuse, ≥75%). Samples with scores of 0 and 1 were considered to have low expression, whereas samples of 2 and 3 were considered to have high expression.

Statistical analysis
--------------------

Correlations between immunohistochemical expression and patient or tumor characteristics were performed by using the χ^2^test or Fisher\'s exact test, as appropriate. Survival curves were estimated by the Kaplan-Meier method, and differences in DFS among groups were compared by using the log-rank test. The COX proportional hazards model was used for multivariate analysis to assess the independent value of TopIIα expression. Two-sided P \< 0.05 was considered statistically significant. All analyses were performed with the SPSS 16.0 software package.

Results
=======

Patient characteristics
-----------------------

We enrolled 151 eligible patients (111 male and 40 female) in this study, who ranged in age from 31 to 81 years, with a median of 55 years, of whom 86 (60%) had a history of smoking. The main histological types included squamous cell carcinoma (41.0%), adenocarcinoma (39.1%), bronchioloalveolar carcinoma (10.0%), large cell carcinoma (6.6%) and adenosquamous (3.3%). Stage I, II and III were diagnosed in 35.8%, 31.1% and 33.1% patients, respectively. In addition, according to pathological T stage or N stage, T1, T2, T3 and T4 were diagnosed in 25.2%, 65.5% 3.3% and 6.0% patients, respectively, and N0, N1 and N2 were diagnosed in 41.1%, 33.1% and 25.8% patients, respectively. The majority had undergone lobectomy (81.5%). All patients received 2 to 8 cycles of adjuvant chemotherapy, of whom 114 (75.5%) finished at least 4 cycles. The main chemotherapy regimens included docetaxel (TXT, 26.5%), GEMZ (33.8%), NVB (26.5%) and paclitaxel (PTX, 13.2%) combined with or without cisplatin (DDP)/carboplatin (CBP). Of the 151 patients, 35 patients (23.2%), most of whom were diagnosed with stage III or N2, received adjuvant radiotherapy. Detailed characteristics are shown in Table [1](#T1){ref-type="table"}.

###### 

Clinical and pathological characteristics and univariate analysis for DFS

  Factors                 Number (%)                Median DFS (months)   P value   
  ----------------------- ------------------------- --------------------- --------- -----------
  Sex                     male                      111 (73.5)            33.99     0.036\*
                          female                    40 (26.5)             21.13     
  Age                     \<55 years                74 (49.0)             21.45     0.330
                          ≥55 years                 77(51.0)              31.97     
  Smoking status          no                        65 (43.0)             22.24     0.305
                          yes                       86 (57.0)             32.99     
  Stage                   I                         54 (35.8)             NR^\#^    0.001\*
                          II                        47 (31.1)             33.64     
                          III                       50 (33.1)             15.18     
  T stage                 T1                        38 (25.2)             NR^\#^    0.03
                          T2                        99 (65.5)             18.76     
                          T3-4                      14 (9.3)              38.16     
  N stage                 N0                        62 (41.1)             NR^\#^    \<0.001\*
                          N1                        50 (33.1)             33.64     
                          N2                        39 (25.8)             13.37     
  Histology               Adenocarcinoma            59 (39.1)             17.41     0.004\*
                          Non- adenocarcinoma       92 (60.9)             48.16     
  Surgery method          Wedge resection           5 (3.3)               17.41     0.958
                          Lobectomy                 123 (81.5)            24.41     
                          Pneumonectomy             23 (15.2)             31.15     
  Chemotherapy regimens   Docetaxel-containing      40 (26.5)             18.60     0.523
                          Vinorelbine- containing   40 (26.5)             48.16     
                          Gemcitabine- containing   51 (33.8)             24.58     
                          Paclitaxel- containing    20 (13.2)             24.41     
  TopIIα                  Low expression            117 (77.5)            19.38     0.012\*
                          High expression           34 (22.5)             NR        
  Ki67                    Low expression            96 (63.6)             22.24     0.517
                          High expression           55 (36.4)             29.37     

\* P \< 0.05 was considered statistically significant; ^\#^NR = not reached

TopIIα and Ki67 expression in NSCLC
-----------------------------------

TopIIα (Figure [1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}) and Ki67 (Figure [1C](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}) were located in the nucleus. TopIIα and Ki67 were highly expressed in 22.5% and 36.4%, respectively, of all 151 patients. Additionally, the expression of TopIIα had a strongly positive correlation with that of Ki67 (r = 0.515, P \< 0.001). Table [2](#T2){ref-type="table"} shows the correlation between TopIIα and Ki67 expression levels and clinical characteristics, including sex, smoking history, histological subtypes, pathological TNM stage, pathological T stage and pathological N stage.

![**Positive expression of TopIIα and Ki67 in non-small cell lung cancer by immunohistochemistry using the EnVision two-step method**. (A) and (B) correspond to ×200 and ×400 magnification of TopIIα respectively; (C) and (D) correspond to ×200 and ×400 magnification of Ki67 respectively](1471-2407-10-621-1){#F1}

###### 

Association between TopIIα and Ki67 expression and clinical variables

  Clinical variables     TopIIα expression (%)   P           Ki67 expression (%)   P                       
  ---------------------- ----------------------- ----------- --------------------- ----------- ----------- ---------
  Sex                                                                                                      
   Male                  25 (22.5)               86 (77.5)   0.998                 39 (35.1)   72 (64.9)   0.584
   Female                9 (22.5)                31 (77.5)                         16 (40.0)   24 (60.0)   
  Smoking status                                                                                           
   No                    16 (24.6)               49 (75.4)   0.591                 25 (38.5)   40 (61.5)   0.651
   Yes                   18 (20.9)               68 (79.1)                         30 (34.9)   56 (65.1)   
  Histology                                                                                                
   Adenocarcinoma        14 (23.7)               45 (76.3)   0.775                 22 (37.3)   37 (62.7)   0.860
   Non- adenocarcinoma   20 (21.7)               72 (78.3)                         33 (35.9)   59 (64.1)   
  Stage                                                                                                    
   I                     10 (18.5)               44 (81.5)   0.177                 13 (24.1)   41 (75.9)   0.034\*
   II                    15 (31.9)               32 (68.1)                         23 (48.9)   24 (51.1)   
   III                   9 (18.0)                41 (82.0)                         19 (38.0)   31 (62.0)   
  T stage                                                                                                  
  T1                     13 (34.2)               25 (65.8)   0.148                 18 (47.4)   20 (52.6)   0.168
  T2                     18 (18.2)               81 (81.8)                         34 (34.3)   65 (65.7)   
  T3-4                   3 (21.4)                11 (78.6)                         3 (21.4)    11 (78.6)   
  N stage                                                                                                  
  N0                     12 (19.4)               50 (80.6)   0.137                 16 (25.8)   46 (74.2)   0.065
  N1                     16 (32.0)               34 (68.0)                         23 (46.0)   27 (54.0)   
  N2                     6 (15.4)                33 (84.6)                         16 (41.0)   23 (59.0)   

\* P \< 0.05 was considered statistically significant

Patient outcomes and clinical predictors
----------------------------------------

After a median follow-up of 35.8 months (ranging from 16.4 - 63.7 months), 80 (53%) patients had metastatic or recurrent tumors and 40 (26.5%) patients had died. Causes of death were NSCLC (37 patients), radiation pneumonitis (1 patient), appearance of a secondary tumor (1 patient) and severe pulmonary infection (1 patient). The median DFS of all 151 patients was 24.3 months and the median OS was not reached. The primary purpose of the study was to assess the associations between clinical characteristics, TopIIα protein expression and efficacy of adjuvant chemotherapy. DFS was more representative than OS as an indirect measure of efficacy, because OS was often affected by treatments other than adjuvant chemotherapy after recurrence or metastasis. DFS was therefore used as the main outcome measure in this study.

Univariate survival analysis showed that sex, pathological TNM stage, pathological N stage, histological subtype (adenocarcinoma or not) and TopIIα expression level were prognostic factors related to DFS, while age, smoking history, surgical methods, pathological T stage, chemotherapy regimens and expression level of Ki67 were of no prognostic significance. Log-rank test indicated that male sex (P = 0.036, Figure [2A](#F2){ref-type="fig"}), earlier pathological TNM stage (P = 0.001, Figure [2B](#F2){ref-type="fig"}) and pathological N stage (P \< 0.001), non-adenocarcinoma (P = 0.004, Figure [2C](#F2){ref-type="fig"}) and high TopIIα expression (P = 0.012, Figure [2D](#F2){ref-type="fig"}) predicted better DFS in postoperative NSCLC patients who received adjuvant chemotherapy. Although the P value for comparison of the survival curves in different T stages was less than 0.05 (P = 0.03), there was no significant difference between T1 stage and T3-4 stage (P = 0.677) or between T2 stage and T3-4 stage (P = 0.245) when pairwise comparisons of the three curves were performed. Only the difference between T1 stage and T2 stage was significant (p = 0.011). Detailed characteristics are also shown in Table [1](#T1){ref-type="table"}.

![**DFS curves according to different clinical and pathological characteristics**. DFS curves according to: (A) sex; (B) pathological TNM stage; (C) histological subtype; (D) TopIIα expression level](1471-2407-10-621-2){#F2}

Correlations between TopIIα expression and the value of adjuvant chemotherapy
-----------------------------------------------------------------------------

It was found that high expression of TopIIα was significantly correlated with better DFS in the patients studied, suggesting that patients with high TopIIα expression benefited more from the adjuvant chemotherapy than those with low TopIIα expression, and that the latter group of patients may be a potential chemotherapy-resistant population. Further stratified analysis of the correlation between the value of adjuvant chemotherapy regimens and TopIIα expression showed that when TopIIα was highly expressed, there were no significant differences in DFS between patients who received chemotherapy with or without TXT (P = 0.712), with or without NVB (P = 0.170), with or without GEMZ (P = 0.415), and with or without PTX (P = 0.763). In addition, when TopIIα expression was low, there were no significant differences in DFS between patients who received chemotherapy with or without TXT, with or without GEMZ, and with or without PTX (Table [3](#T3){ref-type="table"}). However, in patients with low TopIIα expression, the median DFS was 48.16 months for those who received NVB-containing chemotherapy regimens and 16.23 months for those who received regimens without NVB (P = 0.065, Figure [3A](#F3){ref-type="fig"}). Although this difference was marginally insignificant, it is possible that NVB-containing adjuvant chemotherapy is better than others in patients with low TopIIα expression. To ascertain the predictive value of this observation with better certainty, the pooled comparisons as well as pairwise comparisons of DFS among four chemotherapy subgroups were investigated in patients with low and high TopIIα expression. In patients with high TopIIα expression, no significant differences in DFS were observed among the four chemotherapy subgroups regardless of pooled or pairwise comparisons (Table [4](#T4){ref-type="table"}). In patients with low TopIIα expression, the P value was greater than 0.05 (P = 0.267, Figure [3B](#F3){ref-type="fig"}) for the pooled comparison of DFS among the four chemotherapy subgroups. Pairwise comparisons of the four survival curves showed no significant differences in P values between any two subgroups (Table [4](#T4){ref-type="table"} and Figure [3B](#F3){ref-type="fig"}), except the P value between the NVB and TXT subgroups. Pairwise comparison for low TopIIα expression indicated that the NVB-containing regimen was associated with better DFS than the TXT-containing regimen (P = 0.047).

###### 

Comparison of DFS among different chemotherapy groups in patients with low TopIIα expression

  Chemotherapy regimens   Number           Median DFS (months)   P       
  ----------------------- ---------------- --------------------- ------- -------
  Vinorelbine             Containing       29                    48.16   0.065
                          Not containing   88                    16.23   
  Gemcitabine             Containing       39                    14.13   0.530
                          Not containing   78                    22.74   
  Docetaxel               Containing       33                    15.74   0.194
                          Not containing   84                    22.74   
  Paclitaxel              Containing       16                    22.97   0.990
                          Not containing   101                   18.76   

![**Comparison of DFS rates among different chemotherapy subgroups in patients with low TopIIα expression**. (A) depicts comparison of DFS curves between the NVB regimen group and the group of other regimens without NVB; (B) depicts comparison of DFS curves among four chemotherapy subgroups](1471-2407-10-621-3){#F3}

###### 

Pooled and pairwise comparisons of DFS among four chemotherapy regimens in patients with different TopIIα expression levels

  TopIIα expression         Chemotherapy regimens   Vinorelbine (P)   Gemcitabine (P)   Docetaxel (P)   Paclitaxel (P)   P for each stratum
  ------------------------- ----------------------- ----------------- ----------------- --------------- ---------------- --------------------
  Low expression stratum    Vinorelbine                               0.128             0.047\*         0.322            0.267
                            Gemcitabine             0.128                               0.676           0.786            
                            Docetaxel               0.047\*           0.676                             0.429            
                            Paclitaxel              0.322             0.786             0.429                            
  High expression stratum   Vinorelbine                               0.209             0.410           0.437            0.594
                            Gemcitabine             0.209                               0.895           0.902            
                            Docetaxel               0.410             0.895                             0.987            
                            Paclitaxel              0.437             0.902             0.987                            

\* P \< 0.05 was considered statistically significant

Multivariate analysis for DFS
-----------------------------

Multivariate analysis was performed with the COX proportional hazards model to explore whether the prognostic value of TopIIα would disappear when other common prognostic factors were considered. Correlation analysis showed that pathological T stage and pathological TNM stage (P \< 0.001), and pathological N stage and pathological TNM stage (P \< 0.001) were mutually associated. As pathological TNM stage is more widely accepted as a DFS-related parameter than pathological T stage and N stage, subsequent multivariate analysis was performed to incorporate sex, histology, pathological TNM stage and TopIIα expression level as covariates based on the significance of these factors in univariate analysis. The results from the Cox proportional hazard model using the forward stepwise method suggested that the histology subtype (adenocarcinoma vs. non-adenocarcinoma), TNM stage and the TopIIα expression level were independent prognostic factors of DFS in NSCLC (Table [5](#T5){ref-type="table"}). In postoperative patients who received adjuvant chemotherapy, high TopIIα expression was a prognostic marker of longer DFS (hazard ratio 0.442, 95% confidence interval 0.239-0.818, P = 0.009), whereas adenocarcinoma (hazard ratio 2.140, 95% confidence interval 1.373-3.337, P = 0.001) and later TNM stage (hazard ratio 1.688, 95% confidence interval 1.291-2.208, P \< 0.001) were related to a shorter DFS as compared to non-adenocarcinoma and earlier TNM stage.

###### 

Multivariate analysis for factors related to DFS using the COX proportional hazard model

  ----------------------------------------------------------------------------------------
  Factors                              Wald     Hazard ratio   95% CI          P
  ------------------------------------ -------- -------------- --------------- -----------
  Sex                                  0.903    0.784          0.474 - 1.295   0.342

  Histology(adenocarcinoma)            11.277   2.140          1.373 - 3.337   0.001\*

  TNM stage (later)                    14.631   1.688          1.291 - 2.208   \<0.001\*

  Topoisomerase II alpha expression\   6.773    0.442          0.239 - 0.818   0.009\*
  (high expression)                                                            
  ----------------------------------------------------------------------------------------

\* P \< 0.05 was considered statistically significant

Discussion
==========

The results of this study suggest that high TopIIα expression in postoperative NSCLC patients who received adjuvant chemotherapy was associated with better DFS. However, other studies have reported that high TopIIα expression was associated with a poorer survival rate in other types of tumors, including hypopharyngeal carcinoma, breast cancer and salivary gland carcinoma \[[@B20]-[@B23]\]. The reason for this difference is probably that all patients in this study received adjuvant chemotherapy while no patient received it in other studies. We therefore postulate that adjuvant chemotherapy might overcome the adverse biology of cancers that express higher TopIIα protein. Additionally, other recent studies also showed that high expression or amplification of TopIIα promised a good response to chemotherapy, particularly to topoisomerase inhibitors, which are partly consistent with our study \[[@B20],[@B24]\]. The results of our study imply that patients with high TopIIα expression might be able to obtain more benefits from adjuvant chemotherapy than those with low TopIIα expression. Similar results were found in Sève et al.\'s study of the prognostic role of β-tubulinIII in postoperative NSCLC \[[@B25]\]. Sève et al. discovered that high expression of β-tubulinIII was related to poor survival in the absence of adjuvant chemotherapy, though adjuvant chemotherapy prolonged the relapse free survival (RFS) and OS in patients with high β-tubulinIII expression. Therefore, β-tubulinIII acted as not only a prognostic biomarker of DFS but also a predictor of response to adjuvant chemotherapy. To identify predictive factors for survival benefit from treatment, an untreated control group should be included in the study, because a good survival identified in a single-arm trial might simply result from prognostic factors within the cohort, and might not be a result of treatment \[[@B26]\]. However, the major limitation of this study was that patients who did not receive adjuvant chemotherapy were not included. Therefore, we can merely draw the conclusion that TopIIα acted as a prognostic biomarker of DFS in the postoperative NSCLC patients who received adjuvant chemotherapy. A further study including patients with and without adjuvant chemotherapy is required to clarify the predictive role of TopIIα with respect to the benefit of adjuvant chemotherapy. Moreover, TopIIα exhibited an independent significantly prognostic role for DFS, when common prognostic factors, including pathological TNM stage and histological subtype, were considered in multivariate analysis. In addition, the positive correlation between the expression of TopIIα and that of Ki67, as observed in this study, is consistent with prior published reports in NSCLC and breast cancer \[[@B13],[@B27],[@B28]\]. It suggests that higher TopIIα expression is associated with higher cell proliferation in NSCLC, as is the case with Ki67, which is a known cell proliferation marker. Although expression of Ki67 had a strongly positive correlation with expression of TopIIα, Ki67 was of no prognostic significance to DFS.

This is the first study reporting the evaluation of different adjuvant chemotherapy regimens by TopIIα expression level in NSCLC. We found that NVB-containing regimens were associated with better DFS than those without NVB in patients with low TopIIα expression, although the P value was marginally insignificant (P = 0.065). These results are concordant with previous reports related to the mechanism of atypical MDR, which is mediated by TopIIα showing that atypical MDR exhibited cross resistance to many anticancer drugs, except vinca alkaloids \[[@B29],[@B30]\]. However, the result of pooled and pairwise comparisons of DFS between the four chemotherapy subgroups for low or high TopIIα expression showed that only the difference between the NVB and TXT subgroups was significant in patients with low TopIIα expression (P = 0.047). Therefore, it can be deduced that patients with low TopIIα expression are a possible MDR population and that NVB-containing regimens may be better than TXT-containing regimens in these patients. Although there is no sufficient evidence that the efficacy of NVB is better than that of GEMZ and PTX in patients with low TopIIα expression, DFS of the NVB subgroup was no worse than that of the GEMZ and PTX subgroups (Figure [3B](#F3){ref-type="fig"}). In addition, in patients with high TopIIα expression, there were no significant differences in DFS between the different regimens no matter what grouping or comparison methods were performed. Several studies have indicated that high TopIIα expression was a positive predictive factor for response to anthracycline-based chemotherapy in patients with primary breast cancer \[[@B31],[@B32]\]. It is well known that anthracycline in an anti-topoisomerase drug, and should exert strong anti-cancer activity in patients with high TopIIα expression. However, further study is needed to determine whether an anti-topoisomerase-based adjuvant chemotherapy such as etoposide can really bring more benefits to postoperative NSCLC patients with high TopIIα expression than other chemotherapy regimens.

Owing to the limitations of retrospective research, the conclusions drawn from this study need to be further identified and validated in prospective clinical trials. Another deficiency of this study is that the median OS was not reached due to limited follow-up time. Considering that the connection between TopIIα expression and adjuvant chemotherapy was the main purpose of this study, DFS was more representative than OS for evaluating efficacy. Moreover, OS could be influenced by many factors in this retrospective study, which may possibly lead to a negative result for long-term survival. Prospective randomized clinical trials with larger sampling capacities and longer follow-up periods are needed to shed more light on the real relationship between TopIIα expression and the benefit from the given chemotherapy.

This study demonstrated a significant association between TopIIα expression and DFS, in which high TopIIα expression was associated with better DFS than low TopIIα expression, and NVB-containing adjuvant regimens were probably better than TXT-containing regimens in the low TopIIα expressors. Thus, TopIIα may be a good biomarker to predict the value of adjuvant chemotherapy, although further validation is required.

Conclusions
===========

In conclusion, TopIIα expression is an independent prognostic factor of DFS in postoperative NSCLC patients who received adjuvant chemotherapy. Low expression of TopIIα is related to poor DFS. NVB-containing adjuvant regimens are probably better than TXT-containing regimens in patients with low TopIIα expression. However, further investigation is needed to confirm the significance of TopIIα as a prognostic or predictive biomarker before these conclusions can be translated into clinical practice.
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